Analysts at Ascendiant Capital downgraded Cytori Therapeutics CYTX from Buy to Hold and removed the price target of $4.00.
Cytori Therapeutics shares have dropped 21.93% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.
Cytori Therapeutics' shares dropped 30.95% to $1.45 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in